Abstract
additional morbidities associated with malaria, it is necessary to determine an effective therapy for uncomplicated falciparum malaria. 5 as the national, first-line treatment for uncomplicated falciparum malaria, after a data review on chloroquine efficacy revealed widespread chloroquine resistance throughout the country. 6 Resistance to amodiaquine has been reported in Africa and Papua New 7, 8 The combination of artemether and lumefanand well-tolerated in several African studies. However, there has been limited information on the of this combination for treating falciparum malaria, children and adults. The aim of this study was to compare the efficacy of artemether-lumefantrine to artesunate-amodiaquine for treating uncomplicated falciparum malaria in children.
Methods
This randomized, open-label, controlled trial was Panyabungan District Hospital, North Sumatera, was obtained from their parents or guardians. malarial infections, known allergies to the study medications, vomiting after two dosing attempts, intake of any prior anti-malarial drug or withdrawal of consent.
Potential participants were medically screened. After obtaining capillary blood samples, thick and thin presence of malaria parasites. Body weight and body height were recorded. Nutritional status was assessed After enrollment, patients were randomly assigned to receive either artemether-lumefantrine or artesunate-amodiaquine. Medications were administered according to weight-based guidelines.
of artesunate at 4 mg/kg orally combined with lumefantrine was administered twice daily as a the AL group. All drug doses were administered in front of physicians or guardians. Full drug doses were readministered if the patient either spat out Vomiting of readministered medications resulted in withdrawal of the participant from the study.
7 years of age.
were encouraged to come to the clinic if their child felt sick. Study participants were visited at home by members of the study team if a subject was absent on a scheduled visit day.
enced microscopists. Parasitaemia was quantified per selected randomly.
Treatment outcomes were defined as adequate 42, reduction in parasite counts, parasite clearance time and fever clearance time. Drug tolerability and safety were assessed clinically. An adverse event was defined as any undesirable medical occurrence in a patient during the study regardless of its relation to the treatment.
of parasitaemia on day 28, without previously the presence of danger signs or complicated malaria or failure to adequately respond to therapy on days or fever/history of fever in the previous 24 hours and parasitaemia on days 4-28 without previously parasitaemia on days 4-28 without previously meeting criteria for ETF or LTF. Sample size was calculated by a non-inferiority to compare reduction in parasite counts, parasite clearance time and fever clearance time. This study was an intention-to-treat analysis.
Results
( Of the 276 children who completed the study, study as others were lost to follow-up (Figure 1 Also, ETF, LTF and PF were similar in both groups. However, after the third day of observation, the mean parasite clearance time was also significantly shorter four-dose regimen. Oral bioavailability of lumefantrine is highly dependent on its administration with fatty foods, 5 as was reported in several studies from We prepared fat-containing food or drink for participants before they took the medication. resistance status. 7, 8 Several studies have suggested that resistance to amodiaquine occurs because of its structural similarity and mechanism of action to chloroquine. Azlin et al -plicated falciparum malaria had chloroquine resistance We Shorter parasite clearance time occurred in the a Nigerian study in which both groups had similar parasite clearance times. We also noted a higher different from the AL group. Both of these findings suggest that longer parasite clearance times may have been associated with higher risk for treatment failure as seen as in Senegal. 22 Rapid parasite clearance time has been associated with rapid fever clearance time. 22 However, we found that while the parasite clearance time in the AL group was shorter, the fever clearance time was longer than parasite clearance suggests that the fever may be an adverse event from the treatment. 23, 24 Antipyretic use for fever treatment in malarial cases has been associated with longer parasite clearance time. 25 Several of our subjects used antipyretics, but we did not evaluate the correlation between antipyretic use and parasite clearance time.
vomiting, malaise and pruritus. Severe adverse events occurred in two subjects, one with recurrent vomiting and one with an allergic reaction. Both children received second-line treatment medications. Other common adverse events such as headache or tinnitus 25 from the drug combination were not observed in our subjects.
Adverse events in the AL group were nausea, vomiting and malaise. Studies in Uganda 27 and Senegal 23 reported temperature elevation, headache, stomachache and cough in patients taking AL. We did not observe these events in our subjects.
The objective of treating malaria with two or more blood schizontocidal drugs was to decelerate the development of resistance since the drugs have different mechanisms of action and parasitic biochemical targets. 5 Artemisinin and its derivates have gametocidal effects. A limitation in our study parasites. Therefore, we could not determine the gametocyte clearance time in either group. malaria in children. We also found that both AL and References th ed. 
